tradingkey.logo
tradingkey.logo
Search

Tempus AI Inc

TEM
Add to Watchlist
49.860USD
+0.390+0.79%
Close 05/08, 16:00ETQuotes delayed by 15 min
8.95BMarket Cap
LossP/E TTM

Tempus AI Inc

49.860
+0.390+0.79%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+0.79%

5 Days

-9.35%

1 Month

+16.12%

6 Months

-30.54%

Year to Date

-15.56%

1 Year

-18.76%

TradingKey Stock Score of Tempus AI Inc

Currency: USD Updated: 2026-05-08

Key Insights

Tempus AI Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 63 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 76.16.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Tempus AI Inc's Score

Industry at a Glance

Industry Ranking
63 / 384
Overall Ranking
181 / 4494
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Tempus AI Inc Highlights

StrengthsRisks
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 139.14% year-on-year.
Undervalued
The company’s latest PE is -29.14, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 97.14M shares, decreasing 6.95% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 946.00 shares of this stock.

Analyst Rating

Based on 19 analysts
Buy
Current Rating
73.697
Target Price
+48.97%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Tempus AI Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Tempus AI Inc Info

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
Ticker SymbolTEM
CompanyTempus AI Inc
CEOLefkofsky (Eric P)
Websitehttps://investors.tempus.com/
KeyAI